Molecular Bases of Disease
Disassembly of Tau fibrils by the human Hsp70 disaggregation machinery generates small seeding-competent species

https://doi.org/10.1074/jbc.RA120.013478Get rights and content
Under a Creative Commons license
open access

The accumulation of amyloid Tau aggregates is implicated in Alzheimer's disease (AD) and other tauopathies. Molecular chaperones are known to maintain protein homeostasis. Here, we show that an ATP-dependent human chaperone system disassembles Tau fibrils in vitro. We found that this function is mediated by the core chaperone HSC70, assisted by specific cochaperones, in particular class B J-domain proteins and a heat shock protein 110 (Hsp110)-type nucleotide exchange factor (NEF). The Hsp70 disaggregation machinery processed recombinant fibrils assembled from all six Tau isoforms as well as Sarkosyl-resistant Tau aggregates extracted from cell cultures and human AD brain tissues, demonstrating the ability of the Hsp70 machinery to recognize a broad range of Tau aggregates. However, the chaperone activity released monomeric and small oligomeric Tau species, which induced the aggregation of self-propagating Tau conformers in a Tau cell culture model. We conclude that the activity of the Hsp70 disaggregation machinery is a double-edged sword, as it eliminates Tau amyloids at the cost of generating new seeds.

Tau protein
tauopathy
proteostasis
amyloid
protein aggregation
neurodegenerative disease
70-kilodalton heat shock protein (Hsp70)
chaperone DNAJ (DNAJ)
molecular chaperone
prion
Tau
chaperone DnaJ (DnaJ)

Cited by (0)

This article contains supporting information.

Author contributions—E. N., T. R. J., B. B., and C. N.-K. conceptualization; E. N., A. S. W., K. M., L. B., T. K., K. A., W. A. M., R. M., and C. N.-K. resources; E. N. formal analysis; E. N., L. B., W. A. M., T. R. J., R. M., B. B., and C. N.-K. supervision; E. N., A. S. W., H. K., T. R. J., R. M., B. B., and C. N.-K. funding acquisition; E. N. validation; E. N. investigation; E. N. and C. N.-K. visualization; E. N., A. S. W., K. M., L. B., T. K., W. A. M., R. M., and A. M. methodology; E. N. and C. N.-K. writing-original draft; E. N. and C. N.-K. project administration; E. N., A. S. W., T. K., H. K., W. A. M., T. R. J., R. M., A. M., B. B., and C. N.-K. writing-review and editing.

Funding and additional information—This study is part of the PROTEST-70 project within the EU Joint Programme–Neurodegenerative Disease Research (JPND) project. This project is supported through the following funding organizations under the aegis of JPND: France, Agence National de la Recherche (ANR, ANR-17-JPCD-0005-01 to R. M.); Germany, Bundesministerium für Bildung und Forschung (BMBF; 01ED1807A to B. B. and 01ED1807B to C. N.-K.); The Netherlands, Netherlands Organization for Scientific Research (ZonMw; project number 733051076). Funding was also provided by Alzheimer Forschung Initiative e.V. (AFI), grant 17054 (to B. B.), the Baden-Württemberg Stiftung, BWST-ISFIII-029 (to A. S. W. and B. B.), Centre National de la Recherche Scientifique, the Institut de France-Fondation Simone et Cino Del Duca, and the Fondation pour la Recherche Médicale (contract DEQ 20160334896). Cambridge Brain Bank is part of the Human Research Tissue Bank and is supported by the NIHR Cambridge Biomedical Research Centre. This work was supported by the UK Dementia Research Institute, which receives its funding from DRI Ltd., funded by the UK Medical Research Council, Alzheimer’s Society and Alzheimer’s Research UK. This work has also received support from the EU/EFPIA/Innovative Medicines Initiative 2 Joint Undertaking (IMPRiND grant no. 116060). W. A. M. was supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (grant number 206248/Z/17/Z). E. N. was supported by Ph.D. fellowships from the Helmholtz International Graduate School for Cancer Research (DKFZ), the Chica and Heinz Schaller Foundation, and the Studienstiftung des deutschen Volkes.

Conflict of interest—No author has an actual or perceived conflict of interest with the contents of this article.

Present address for Thomas R. Jahn: AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

Abbreviations—The abbreviations used are:

    AD

    Alzheimer's disease

    HD

    Huntington's disease

    Hsp

    heat shock protein

    HSPA4

    heat shock protein family A (Hsp70) member 4 (APG2)

    HSPA8

    heat shock protein family A (Hsp70) member 8 (HSC70)

    NEF

    nucleotide exchange factor

    PD

    Parkinson's disease

    TEM

    transmission electron microscopy

    ThT

    thioflavin T

    ANOVA

    analysis of variance.